04:39 PM EDT, 04/04/2024 (MT Newswires) -- Invivyd ( IVVD ) said late Thursday its Pemgarda injection to prevent coronavirus is available for purchase in the US.

Pemgarda obtained emergency use authorization from the US Food and Drug Administration on March 22 for the prevention of COVID-19 in some adults and adolescents with moderate-to-severe immune compromise, the company said.

Pemgarda is expected to generate net product revenue between $150 million and $200 million in the full year 2024, Invivyd ( IVVD ) said.

The company said that, based on this guidance as well as its optimization of operating expenses, it expects to conclude 2024 with at least $55 million in cash and cash equivalents.

Invivyd ( IVVD ) shares were rising almost 2% in after-hours trading.

Price: 3.65, Change: +0.07, Percent Change: +1.96